



April 15, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2012-005793-63/ Novartis Protocol ID CLIK066A2202

A multi-center, randomized, double-blind, double-dummy, parallel-group dose-finding study to evaluate the change in HbA1c after 12 weeks monotherapy with seven doses of LIK066 compared with placebo or sitagliptin in patients with type 2 diabetes

Trial CLIK066A2202 was cancelled with no patient enrollment and as such, no results will be reported.